PCOS Renamed to PMOS to Reflect Broader Health Impacts on Women
Polycystic ovary syndrome (PCOS), a condition affecting millions of women, has been renamed to polyendocrine metabolic ovarian syndrome (PMOS). This change, announced in a global consensus published in The Lancet, aims to better reflect the condition's wide-ranging effects on metabolic, endocrine, cardiovascular, reproductive, dermatological systems, and mental health. The decision involved input from over 50 academic, clinical, and patient organizations, as well as feedback from more than 14,000 women. The previous name was considered misleading as it suggested ovarian cysts were the main issue, whereas PMOS affects multiple systems, often leading to irregular periods, excess androgen levels, and increased risk of diabetes and heart disease. The new name is expected to improve diagnosis, reduce stigma, and capture the full scope of the condition. 
